CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0012532: Chronic painHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (18)


Name (Synonyms) Correlation
drug2576 Self-Compassion for Chronic Pain Virtual Group Treatment Program Wiki 0.35
drug3225 chronic pain team Wiki 0.35
drug894 Digital Health Online Platform Wiki 0.35
drug915 Dornase Alfa Wiki 0.35
drug380 Baricitinib or Anakinra Wiki 0.35
drug3220 chiropractic team Wiki 0.35
drug2839 Tele-Yoga Therapy Wiki 0.35
drug611 Cannabis, Medical Wiki 0.35
drug908 Disulfiram Wiki 0.35
drug1459 Intervention program Wiki 0.35
drug538 COVID-19 FACILITY Wiki 0.35
drug891 Dietary counselling on Food Groups according to IYC Feeding practices, WHO Wiki 0.35
drug1036 Exercise Group Wiki 0.35
drug886 Diet tracking and survey Wiki 0.35
drug902 Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care Wiki 0.35
drug3437 questionnaire assesment Wiki 0.32
drug2707 Standard of care Wiki 0.08
drug2122 Placebo Wiki 0.02

Correlated MeSH Terms (29)


Name (Synonyms) Correlation
D059350 Chronic Pain NIH 1.00
D000070627 Chronic Traumatic Encephalopathy NIH 0.35
D000690 Amyotrophic Lateral Sclerosis NIH 0.35
D016472 Motor Neuron Disease NIH 0.35
D005879 Tourette Syndrome NIH 0.35
D013122 Spinal Diseases NIH 0.25
D012640 Seizures NIH 0.25
D000755 Anemia, Sickle Cell NIH 0.25
D001714 Bipolar Disorder NIH 0.25
D005356 Fibromyalgia NIH 0.20
D001927 Brain Diseases NIH 0.18
D003095 Collagen Diseases NIH 0.18
D010300 Parkinsonian NIH 0.18
D003424 Crohn Disease NIH 0.16
D012216 Rheumatic Diseases NIH 0.14
D000070642 Brain Injuries, Traumatic NIH 0.13
D015212 Inflammatory Bowel Diseases NIH 0.13
D001172 Arthritis, Rheumatoid NIH 0.12
D001930 Brain Injuries, NIH 0.12
D012598 Scoliosi NIH 0.11
D009103 Multiple Sclerosis NIH 0.10
D001168 Arthritis NIH 0.10
D013577 Syndrome NIH 0.07
D040921 Stress Disorders, Traumatic NIH 0.07
D014947 Wounds and Injuries NIH 0.07
D013313 Stress Disorders, Post-Traumatic NIH 0.06
D004194 Disease NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.02
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (9)


Name (Synonyms) Correlation
HP:0006802 Abnormal anterior horn cell morphology HPO 0.35
HP:0007354 Amyotrophic lateral sclerosis HPO 0.35
HP:0100754 Mania HPO 0.25
HP:0001250 Seizure HPO 0.20
HP:0001298 Encephalopathy HPO 0.18
HP:0100280 Crohn's disease HPO 0.16
HP:0002037 Inflammation of the large intestine HPO 0.13
HP:0001370 Rheumatoid arthritis HPO 0.12
HP:0001369 Arthritis HPO 0.10

There are 8 clinical trials

Clinical Trials


1 Outcomes Mandate National Integration With Cannabis as Medicine

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

NCT03944447 Chronic Pain Chronic Pain Syndrome Chronic Pain Due to Injury Chronic Pain Due to Trauma Fibromyalgia Seizures Hepatitis C Cancer Crohn Disease HIV/AIDS Multiple Sclerosis Traumatic Brain Injury Sickle Cell Disease Post Traumatic Stress Disorder Tourette Syndrome Ulcerative Colitis Glaucoma Epilepsy Inflammatory Bowel Diseases Parkinson Disease Amyotrophic Lateral Sclerosis Chronic Traumatic Encephalopathy Anxiety Depression Insomnia Autism Opioid-use Disorder Bipolar Disorder Covid19 SARS-CoV Infection Drug: Cannabis, Medical
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic Wounds and Injuries
HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

Primary Outcomes

Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

Measure: Treatment of Symptoms

Time: Five years

Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

Measure: Monitoring Adverse Events

Time: Five years

Secondary Outcomes

Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

Measure: Cannabis Impact on Quality of Life

Time: Five years

Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

Measure: Cannabis Route and Dosing

Time: Five years

2 Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak

Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.

NCT04351399 Sars-CoV2 Rheumatic Diseases Rheumatoid Arthritis Chronic Pain Other: questionnaire assesment
MeSH:Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain
HPO:Arthritis Chronic pain Polyarticular arthritis Rheumatoid arthritis

Primary Outcomes

Measure: Frequency of RA patients with emotional impact (feeling of isolation)

Time: maximum 1 week from baseline on

Secondary Outcomes

Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.

Measure: self-reported questionnaire for painful

Time: maximum 1 week from baseline on

3 Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak

In the context of quarantine with COVID-19, we will study the experience and psychological impact of pain in adult patients living with chronic pain. We will evaluate the link between the question of physical and psychological confinement in the experience of pain in this particular situation

NCT04353011 Sars-CoV2 Chronic Pain Other: questionnaire assesment
MeSH:Chronic Pain
HPO:Chronic pain

Primary Outcomes

Measure: Hospital Anxiety and Depression Scale questionnaire

Time: 1 week from baseline on

Secondary Outcomes

Measure: Quality of life (SF36)

Time: 1 week from baseline on

Measure: self-reported questionnaire for painful

Time: 1 week from baseline on

Measure: qualitive questionnaire

Time: 1 week from baseline on

4 The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.

The quarantine during COVID-19 pandemic has changed daily routine. Staying at home for prolonged periods of time can pose a significant challenge for patients with chronic pain. The purpose of the current study is to investigate how the quarantine effects of psychosocial factors, quality of life, sleep, nutrition and physical activity in patients with chronic musculoskeletal pain. Another purpose is to examine whether a telerehabilitation exercise program is effective during the lockdown period.

NCT04381000 Chronic Pain Other: Exercise Group
MeSH:Chronic Pain
HPO:Chronic pain

Primary Outcomes

Description: To measure the levels of anxiety and depression Hospital Anxiety and Depression Scale (HADS), will be used. Patients have to score 14 opinions. Seven of the items relate to anxiety and seven relate to depression. A cut-off point of 8/21 for anxiety or depression has been recommended.

Measure: Anxiety and Depression

Time: Change From Baseline in HADS at 40 days

Description: To measure quality of life, EQ-5D-3L will be used. The EQ-5D-3L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

Measure: Quality of Life and overall health

Time: Change From Baseline in EQ-5D-3L at 40 days

Description: The Numeric Pain Rating Scale (NPRS) is a unidimensional measure of pain intensity in adults and it will be used in the current study. The most commonly used is the 11-item NPRS. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").The NPRS is a valid and reliable scale to measure pain intensity. In this study, will rate current pain intensity and mean pain intensity during the past 7 days.

Measure: Pain Intensity

Time: Change From Baseline in NPRS Scores at 40 days

Secondary Outcomes

Description: The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in the older adult. PSQI will be used to assess quality and patterns of sleep in the current study. PSQI differentiates "poor" from "good" sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month. The client self-rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of "5" or greater indicates a "poor" sleeper. Although there are several questions that request the evaluation of the client's bed mate or roommate, these are not scored, nor reflected in the attached instrument. An update to the scoring: if 5 is not complete or the value is missing, it now counts as a "0".

Measure: Quality and patterns of sleep

Time: Change From Baseline in PSQI Scores at 40 days

Description: Patients' illness perceptions will be measured based on the Brief Illness Perception Questionnaire (BIPQ). The patient has to rate 8 statements on a 10-point scale (1-10). The higher the score, the greater is the extent to which the patient's illness perceptions are threatening him or her.

Measure: Patients' illness perceptions

Time: Change From Baseline in BIPQ Scores at 40 days

Description: Disability will be assessed using Oswestry Disability Index (ODI) that present ten sections cover Pain, Personal Care, Lifting, Walking, Sitting, Standing, Sleeping, Sex Life, Social Life, and Traveling. Each section has six statements reflecting an increasing level of disability. Respondents choose the statement that most applies to them in each section. The first statement is scored 0; the second is scored 1 and so on to 5 for the last statement. The sum of the section scores is divided by 50 if all sections are completed and multiplied by 100 for the final percentage score.

Measure: Disability

Time: Change From Baseline in ODI Scores at 40 days

5 Early Care, Therapeutic Education, and Psychological Intervention for the Management of Post-intensive Care Syndrome and Chronic Pain After Coronavirus Disease 2019 Infection. Simple-blind, Controlled, Randomized Trial.

COVID-19 (coronavirus 2019) disease has led to a large number of hospital admissions, many of which require admission to intensive care (ICU). Post-intensive care syndrome (PICS) is defined as deterioration or worsening of previous deterioration in the mental, physical or cognitive status that appears as a consequence of a critical illness and which persists after acute hospital care. Also, there is evidence that patients who survive a critical illness have a high prevalence of moderate to extreme chronic pain. Patients with COVID-19 disease are an especially susceptible population to develop PICS due to acute respiratory distress syndrome (ARDS) survivors have significant long-term deterioration in mental, cognitive, and functional health. This study hypothesis is that a specific care program based on early therapeutic education and psychological intervention improves the quality of life of patients at risk of developing PICS and chronic pain after COVID-19 disease.

NCT04394169 Post ICU Syndrome Chronic Pain Covid-19 Behavioral: Intervention program
MeSH:Syndrome Chronic Pain
HPO:Chronic pain

Primary Outcomes

Description: Health-related quality of life reported by the patient assessed through the visual analogue scale of the EQoL 5D/5L questionnaire at six months after discharge. [European quality of life 5 dimensions/5 levels ; from 0 (the worst imaginable health) to 100 (the best imaginable health) ]

Measure: Impact of intervention program on health-related quality of life (VAS)

Time: Six months after discharge

Secondary Outcomes

Description: Health-related quality of life reported by the patient assessed through the visual analogue scale of the EQoL 5D / 5L questionnaire at three months after discharge. [European quality of life 5 dimensions/5 levels ; from 0 (the worst imaginable health) to 100 (the best imaginable health)]

Measure: Impact of intervention program on health-related quality of life (VAS)

Time: Three months after discharge.

Description: Health-related quality of life reported by the patient assessed through health index of the EQoL 5D/5L questionnaire at three months after discharge. [European quality of life 5 dimensions/5 levels ; the questionnaire assesses quality of life in study participants according to 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each scored according to a scale of 1 (no problems) to 5 (indicating extreme problems) and generating a 5-digit code corresponding to quality of life]

Measure: Impact of intervention program on health-related quality of life (Index)

Time: Three months after discharge

Description: Health-related quality of life reported by the patient assessed through health index of the EQoL 5D/5L questionnaire at six months after discharge. [European quality of life 5 dimensions/5 levels ; the questionnaire assesses quality of life in study participants according to 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each scored according to a scale of 1 (no problems) to 5 (indicating extreme problems) and generating a 5-digit code corresponding to quality of life]

Measure: Impact of intervention program on health-related quality of life (Index)

Time: Six months after discharge

Description: Chronic pain intensity defined by BPI questionnaire (short version), at three and six months after discharge. [Brief pain inventory; A multidimensional questionnaire that evaluates pain intensity in the last 24 hours (worst, lowest, average) and current (right now). The questions are rated on a scale of 0 to 10, with 10 being the worst possible value. Subsequently, the average intensity score (BPI intensity score) is calculated.]

Measure: Impact of intervention program on chronic pain (intensity)

Time: Three and six months after discharge.

Description: Limitation of daily activities due to chronic pain, defined by BPI (short version), at three and six months after discharge. [Brief pain inventory; Multidimensional questionnaire that assesses the impact of pain on daily activities (general activity, encouragement, work, relationships with other people, sleep, enjoying life and the ability to walk). The questions are rated on a scale of 0 to 10, with 10 being the worst possible value. Subsequently, the mean score of the responses related to pain interference in activities (BPI interference score) is calculated.]

Measure: Impact of intervention program on chronic pain (limitation of daily activities)

Time: Three and six months after discharge.

Description: Pain catastrophization assessed by Pain Catastrophizing Scale at three and six months after hospital discharge. [Pain Catastrophizing Scale; Consisting of 13 questions that explore the frequency of thoughts and feelings that the interviewees have in the presence of current or anticipated pain, which are grouped into three scoring subscales (magnification, rumination and defenselessness). Each question is rated on a 5-point scale (0: not at all; 4: all the time). Being the maximum total score of 52 points.]

Measure: Impact of intervention program on chronic pain (Pain catastrophization)

Time: Three and six months after discharge.

Description: Clinically significant anxiety or depression symptoms prevalence at three and six months, assessed by the HAD test. [hospital anxiety and depression test; 14 questions, with two subscales, one for anxiety and the other for depression, with seven items each, the maximum score is 21 for each subscale. The cut-off points from zero to seven imply the absence of clinically relevant anxiety and depression, from eight to ten symptoms that require consideration and from 11 to 21 reports the presence of relevant symptoms, with a very probable diagnosis of anxiety or depression.]

Measure: Impact of intervention program on anxiety or depression incidence

Time: Three and six months after discharge.

Description: Probable post-traumatic stress syndrome prevalence at three and six months after discharge assessed by the DSM ( Diagnostic and Statistical Manual of Mental Disorders) V PTSD Checklist questionnaire (PCL-5) [PTSD Checklist questionnaire; It contains 20 questions that correspond to the DSM V PTSD (Post Traumatic Stress Disorder) criteria. Participants rated their symptoms on a scale of 0 (not at all), 1 (slightly), 2 (moderately), 3 (quite) to 4 (extremely), with a score ranging from 0 to 80. A total of the severity of the symptoms can be made, adding the score of each question (interval 0-80). The severity of each symptom can be evaluated, adding the score of the questions. The cut-off point to use for a provisional diagnosis of PTSD is 31 points.]

Measure: Impact of intervention on probable post-traumatic stress syndrome incidence

Time: Three and six months after discharge.

6 A Self-compassion Group-based Treatment for Chronic Pain Via Video Conferencing During the COVID-19 Pandemic: Feasibility Study for a Potential New Mode of Treatment Delivery

As a result of COVID-19 and measures taken by the Canadian Government to reduce the transmission of the virus, in-person psychology services have been suspended. Psychology services are now being conducted via video conferencing. The purpose of the current project is to pilot-test a 6-week Self Compassion Treatment for Chronic Pain delivered virtually, in order to understand its utility in the current environment. The treatment is to be delivered through a secure professional ZOOM licence. Objective 1 of the project is to assess the feasibility and acceptability of attending the treatment group through virtual participation. Objective 2 is to assess the effectiveness of the group treatment in improving self-compassion, mental health, relationship with pain, and quality of life.

NCT04413006 Chronic Pain Behavioral: Self-Compassion for Chronic Pain Virtual Group Treatment Program
MeSH:Chronic Pain
HPO:Chronic pain

Primary Outcomes

Description: Change over time in scores on the Self-Compassion Scale (SCS) (score range is 12-60 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Self-Compassion Scale (SCS)

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Pain Disability Index (score range is 0-70 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Pain Disability Index

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Secondary Outcomes

Description: Change over time in scores on the on the Chronic Pain Acceptance Questionnaire - 8 (CPAQ-8) (score range is 0-48 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Chronic Pain Acceptance Questionnaire - 8

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the on the Pain Catastrophizing Scale-6 (PCS-6) (score range is 0-24 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Pain Catastrophizing Scale -6

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4 (PSEQ-4) (score range is 0-24 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Numeric Rating Scale (NRS) for pain (score range is 0-10 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Pain Intensity

Time: at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Patient Health Questionnaire-9 (PHQ-9) (score range is 0-27 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Depression Symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Generalized Anxiety Scale (GAD-7) (score range is 0-21 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Changes over time in Anxiety Symptoms as measured by the Generalized Anxiety Scale-7

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Change over time in scores on the Physical Health and Mental Health Quality of Life scores from the PROMIS GLOBAL-10 (score range is 7-35 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Change over time in Quality of Life as measured by the PROMIS GLOBAL- 10

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Description: Changes over time in score on the Mindfulness Attention and Awareness Scale (MAAS) (score range is 15-90 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)

Measure: Changes over time in Mindfulness

Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months later

Other Outcomes

Description: Scores on the Client Satisfaction Questionnaire

Measure: Client Satisfaction

Time: post treatment (6 weeks after beginning the treatment)

7 Tele- Yoga Therapy for Patients With Chronic Pain During Covid-19 Lockdown: A Prospective Non-randomized Single Arm Clinical Trial

Chronic pain is highly prevalent and associated with a large symptom burden, that is had been more concerning during Covid-19 outbreak and lockdown. Benefits of yoga in chronic pain management are very well known. With this background we developed Tele-Yoga therapy program and evaluated the success of this single arm study.

NCT04457388 Chronic Pain Other: Tele-Yoga Therapy
MeSH:Chronic Pain
HPO:Chronic pain

Primary Outcomes

Description: visual-analogic scale (VAS), using pain level from "no pain" (0) to "worst imaginable pain" (10)

Measure: Pain Intensity

Time: From baseline to 6-week post intervention

Secondary Outcomes

Description: Pain Disability Index (PDI) using seven rating scales, structured in Likert form, from "no disability" (0) to "worst disability" (10)

Measure: Pain Disability

Time: From baseline to 6-week post intervention

Description: Hospital Anxiety Depression Scale, consisting of 7 scales for measuring anxiety levels

Measure: Anxiety

Time: From Baseline to 6-week post intervention

Description: Hospital Anxiety Depression Scale, consisting of 7 scales for measuring depression levels

Measure: Depression

Time: From baseline to 6-week post intervention

8 An Observational Study of Integrated Chronic Pain Management in a Community Health Center

This was a prospective observational study with the primary objective of quantifying a change in pain scores after 6-12 months of two separate interventions within the study site (pain team and chiropractic team). Target enrollment was 30 participants for each intervention. The primary outcome was a change from baseline of the Pain Disability Questionnaire (PDQ), the study tool. Secondary outcomes were reduction of opioid dose by morphine equivalent daily dose, and its effect on PDQ scores.

NCT04490291 Chronic Pain Spine Disease Other: chronic pain team Other: chiropractic team
MeSH:Spinal Diseases Chronic Pain
HPO:Chronic pain

Primary Outcomes

Description: 6-12 month follow up pain score - (minus) baseline. scores range from 0 (no pain or disability) to 150 (severe pain and disability)

Measure: change in Pain Disability Questionnaire (PDQ) score

Time: 6-12 month

Secondary Outcomes

Description: ability to successfully wean off opioid prescription

Measure: prescription opioid weaning

Time: 6-12 months


HPO Nodes